McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia—an overview. JAMA Psychiatry. 2020;77:201.

PubMed  Google Scholar 

McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67–76.

PubMed  Google Scholar 

Biedermann F, Fleischhacker WW. Psychotic disorders in DSM-5 and ICD-11. CNS Spectr. 2016;21:349–54.

PubMed  Google Scholar 

Seidman LJ, Mirsky AF. Evolving Notions of Schizophrenia as a Developmental Neurocognitive Disorder. J Int Neuropsychol Soc. 2017;23:881–92.

PubMed  Google Scholar 

Brisch R, Saniotis A, Wolf R, Bielau H, Bernstein H-G, Steiner J, et al. The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front Psychiatry. 2014;5:47.

PubMed  PubMed Central  Google Scholar 

Sonnenschein SF, Grace AA. Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia. Neuropharmacology. 2020;163:107632.

CAS  PubMed  Google Scholar 

Shen L-H, Liao M-H, Tseng Y-C. Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders. J Biomed Biotechnol. 2012;2012:259349.

PubMed  PubMed Central  Google Scholar 

Abi-Dargham A. From ‘bedside’ to ‘bench’ and back: a translational approach to studying dopamine dysfunction in schizophrenia. Neurosci Biobehav Rev. 2020;110:174–9.

CAS  PubMed  Google Scholar 

Sonnenschein SF, Gomes FV, Grace AA. Dysregulation of midbrain dopamine system and the pathophysiology of schizophrenia. Front Psychiatry. 2020;11:613.

PubMed  PubMed Central  Google Scholar 

Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharm Toxicol. 1963;20:140–4.

CAS  Google Scholar 

Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 1976;261:717–9.

CAS  PubMed  Google Scholar 

Wadenberg M. Dopamine D2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology. 2001;25:633–41.

CAS  PubMed  Google Scholar 

Demjaha A, Egerton A, Murray RM, Kapur S, Howes OD, Stone JM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry. 2014;75:e11–13.

CAS  PubMed  Google Scholar 

Feber L, Peter NL, Chiocchia V, Schneider-Thoma J, Siafis S, Bighelli I, et al. Antipsychotic drugs and cognitive function: a systematic review and network meta-analysis. JAMA Psychiatry. 2025;82:47.

PubMed  Google Scholar 

Correll CU, Schooler NR. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat. 2020;16:519–34.

PubMed  PubMed Central  Google Scholar 

Grace AA, Uliana DL. Insights into the mechanism of action of antipsychotic drugs derived from animal models: standard of care versus novel targets. Int J Mol Sci. 2023;24:12374.

CAS  PubMed  PubMed Central  Google Scholar 

Greenwood KE, Landau S, Wykes T. Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy. Schizophr Bull. 2005;31:910–21.

PubMed  Google Scholar 

Bowie CR, Harvey PD. Cognitive deficits and functional outcome in schizophrenia. Neuropsychiatr Dis Treat. 2006;2:531–6.

PubMed  PubMed Central  Google Scholar 

Luo H, Zhao Y, Fan F, Fan H, Wang Y, Qu W, et al. A bottom-up model of functional outcome in schizophrenia. Sci Rep. 2021;11:7577.

CAS  PubMed  PubMed Central  Google Scholar 

Heckers S, Konradi C. Hippocampal pathology in schizophrenia. Curr Top Behav Neurosci. 2010;4:529–53.

PubMed  Google Scholar 

Lieberman JA, Girgis RR, Brucato G, Moore H, Provenzano F, Kegeles L, et al. Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention. Mol Psychiatry. 2018;23:1764–72.

CAS  PubMed  PubMed Central  Google Scholar 

Schobel SA, Chaudhury NH, Khan UA, Paniagua B, Styner MA, Asllani I, et al. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron. 2013;78:81–93.

CAS  PubMed  PubMed Central  Google Scholar 

Zhang ZJ, Reynolds GP. A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia. Schizophr Res. 2002;55:1–10.

PubMed  Google Scholar 

Lodge DJ, Behrens MM, Grace AA. A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia. J Neurosci. 2009;29:2344–54.

CAS  PubMed  PubMed Central  Google Scholar 

Lodge DJ, Grace AA. Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. J Neurosci. 2007;27:11424–30.

CAS  PubMed  PubMed Central  Google Scholar 

Modinos G, Allen P, Grace AA, McGuire P. Translating the MAM model of psychosis to humans. Trends Neurosci. 2015;38:129–38.

CAS  PubMed  Google Scholar 

Moore H, Jentsch JD, Ghajarnia M, Geyer MA, Grace AA. A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol Psychiatry. 2006;60:253–64.

CAS  PubMed  PubMed Central  Google Scholar 

Gomes FV, Rincón-Cortés M, Grace AA. Adolescence as a period of vulnerability and intervention in schizophrenia: Insights from the MAM model. Neurosci Biobehav Rev. 2016;70:260–70.

PubMed  PubMed Central  Google Scholar 

Grace AA. Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression. Nat Rev Neurosci. 2016;17:524–32.

CAS  PubMed  PubMed Central  Google Scholar 

Lodge DJ, Grace AA. Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. Trends Pharm Sci. 2011;32:507–13.

CAS  PubMed  Google Scholar 

Singh R, Hahn MK, Bansal Y, Agarwal SM, Remington G. Evenamide: a potential pharmacotherapeutic alternative for treatment-resistant schizophrenia. Int J Neuropsychopharmacol. 2024;27:pyae005.

PubMed  PubMed Central  Google Scholar 

Singh R, Sharma R, Kumar B, Kuhad A, Kuhad A. Evenamide hydrochloride. Voltage-gated sodium channel blocker, treatment of schizophrenia. Drugs Future. 2019;44:693.

Google Scholar 

Anand R, Forrest EC, Hartman RD, Graham SM, Faravelli L. Evenamide, a voltage-gated sodium channel blocker in the treatment of schizophrenia: results from a placebo-controlled study. Eur Neuropsychopharmacol. 2017;27:S947–8.

Google Scholar 

Chahine M, Chatelier A, Babich O, Krupp J. Voltage-gated sodium channels in neurological disorders. CNSNDDT. 2008;7:144–58.

CAS  Google Scholar 

Anand R, Bortolato M, Faravelli L. Glutamate modulation by evenamide, a Na+ channel blocker, may benefit treatment resistant schizophrenic (TRS) patients not responding to clozapine. Eur Neuropsychopharmacol. 2019;29:S540–1.

Google Scholar 

Bortolato M, Faravelli L, Anand R. T36. The antipsychotic-like properties of evenamide (NW-3509) reflect the modulation of glutamatergic dysregulation. Schizophr Bull. 2018;44:S126–7.

PubMed Central  Google Scholar 

Faravelli L, Anand R, Forrest E. Evenamide (formerly NW-3509) targets new mechanisms, and represents a new approach to the management of untreated symptoms in schizophrenia. Eur Neuropsychopharmacol. 2016;26:S588.

Google Scholar 

Anand R, Forrest EC, Hartman RD, Graham SM, Faravelli L. T48. ANTIPSYCHOTIC EFFICACY OF EVENAMIDE (NW-3509) IS DUE TO MODULATION OF GLUTAMATERGIC DYSREGULATION. Schizophrenia Bull. 2018;44:S132.

Google Scholar 

Anand R, Turolla A, Chinellato G, Roy A, Hartman RD. Phase 2 results indicate evenamide, a selective modulator of glutamate release, is associated with clinically important long-term efficacy when added to an antipsychotic in patients with treatment-resistant schizophrenia. Int J Neuropsychopharmacol. 2023;26:523–8.

CAS  PubMed  PubMed Central  Google Scholar 

Anand R, Turolla A, Chinellato G, Roy A, Hartman RD. Therapeutic effect of evenamide, a glutamate inhibitor, in patients with treatment-resistant schizophrenia (TRS): final, 1-year results from a phase 2, open-label, rater-blinded, randomized, international clinical trial. Int J Neuropsychopharmacol. 2024;28:pyae061.

PubMed  PubMed Central  Google Scholar 

Anand R, Turolla A,